Cancer Therapy
High dose/short duration chemotherapy plus PBSC is safe and effective for relapsed NHL
Published in Blood Weekly, June 8th, 2006
"A simplified schedule of high-dose chemotherapy consisting of cyclophosphamide (60 mg/kg/day for 2 days), etoposide (15 mg/kg/day for 2 days) and carboplatine (400 mg/m2/day for 2 days), together with autologous noncryopreserved peripheral blood stem cells was used for treatment of relapsed (29 patients) and refractory (three patients) patients with non-Hodgkin's lymphoma (NHL).
"The use of such granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2006-06-08)
More Articles from Blood Weekly
- Angiology
Vascular walls are reservoirs for progenitor cells that propel postnatal vasculogenesis - Bioartificial Liver
Cold storage prior to culture or therapy prolongs bioartificial liver transportation time - Blood Safety
Transfusion-transmitted Klebsiella pneumoniae fatalities in U.S. are reported - Blood Vessel Tissue Engineering
Chitosan-derived sandwich tubular scaffold feasible for blood vessel tissue engineering - Stem Cell Research
Data supports importance of family umbilical cord blood banking - Angiology
Carotid angioplasty with a novel stent implant effective in an experimental model - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
